Dr. Jingrong Jean Cui is a distinguished oncology drug designer and the lead inventor of numerous oncology treatments and clinical compounds.
She has over 20 years of experience in drug discovery and project management with various biotech and pharma companies, including Pfizer and Pharmacia/SUGEN. She is the scientific founder of San Diego-based Turning Point Therapeutics (TP), a biotech company focused on targeted therapies for the treatment of cancer patients. Additionally, in July 2020, Dr. Cui co-founded—and serves as president and CEO of—BlossomHill Therapeutics, a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
In 2019, TP went public with Dr. Cui in the role of chief scientific officer. Previously, she worked for Pfizer as a principal scientist and research fellow between 2003 to 2013. Before that, she was with Pharmacia/SUGEN as a project and group leader between 1999 to 2003.
A TP, she emphasized solving issues of drug resistance in targeted therapies and developed a distinctive macrocyclic platform to tackle resistance issues systematically. This work resulted in the development of three clinical compounds within six years of the company’s founding.
While at Pfizer, she was the lead inventor on precision oncology medicines, Crizotinib and Lorlatinib, and she also worked on multiple oncology projects, including SUTENTTM a treatment for progressive, well-differentiated pancreatic neuroendocrine tumors (pNET).
Along with her chemistry team, Dr. Cui was selected for the 2011 National Inventor of the Year Award for her work on Crizotinib. She has received two Worldwide R&D Achievement Awards as well as an Innovation Award from Pfizer. Additionally, she was recognized as an honoree in the American Chemical Society’s Heroes of Chemistry Program for the discovery and development of Crizotinib in 2013, and she was the recipient of the inaugural CABS K. Fong Award in Life Sciences, also in 2013.
Dr. Cui earned both her bachelor’s and master’s degrees in chemistry from the University of Science and Technology of China. She holds a Ph.D. in organic chemistry from The Ohio State University, and she completed her postdoctoral training at the University of California-Berkeley.
What is Jingrong Jean Cui's net worth?
The estimated net worth of Jingrong Jean Cui is at least $76.11 million as of June 4th, 2020. Dr. Cui owns 1,001,298 shares of Turning Point Therapeutics stock worth more than $76,108,661 as of November 25th. This net worth estimate does not reflect any other investments that Dr. Cui may own. Learn More about Jingrong Jean Cui's net worth.
How do I contact Jingrong Jean Cui?
Has Jingrong Jean Cui been buying or selling shares of Turning Point Therapeutics?
Jingrong Jean Cui has not been actively trading shares of Turning Point Therapeutics over the course of the past ninety days. Most recently, Jingrong Jean Cui sold 18,500 shares of the business's stock in a transaction on Monday, June 8th. The shares were sold at an average price of $63.45, for a transaction totalling $1,173,825.00. Following the completion of the sale, the director now directly owns 1,001,298 shares of the company's stock, valued at $63,532,358.10. Learn More on Jingrong Jean Cui's trading history.
Who are Turning Point Therapeutics' active insiders?
